Evaluation of 3-5 months add-on therapy with montelukast in patients with non-controlled asthma in Austria: The star open-label, real-world, observational study

Current Medical Research and Opinion

Volumn 26, Issue 3, 2010, Pages 561-570

  Schlick, Werner ^a   Pohl, Wolfgang ^b   Pfeiffer, Karl P ^c   Aigner, Kurt ^d   Forche, Günter ^a   Kneussl, Meinhard ^d   Zwick, Hartmut ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Augenabteilung KH Hietzing   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d Department of Pneumology Elisabethinen Linz ^*  (Austria)

Author keywords

Add; Asthma; Leukotriene receptor antagonist; Montelukast; On treatment; Quality of life; Symptoms control; Treatment satisfaction

Indexed keywords

ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CROMONE; MONTELUKAST; STEROID; THEOPHYLLINE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADOLESCENT; ADULT; ANXIETY; ARTICLE; CHEST TIGHTNESS; CHILD; CLINICAL TRIAL; COUGHING; DAILY LIFE ACTIVITY; EXERCISE TOLERANCE; FEMALE; FRUSTRATION; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD PERSISTENT ASTHMA; MODERATE PERSISTENT ASTHMA; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; SCHOOL CHILD; SLEEP; WHEEZING; WORK CAPACITY;

ACETATES; ADOLESCENT; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; AUSTRIA; CHILD; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; QUESTIONNAIRES; QUINOLINES; TIME FACTORS;

EID: 76949090418     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903523021     Document Type: Article

References (24)

1. Dahl R, Bjermer L. Nordic consensus report on asthma management. Respiratory Med 2000;94:299-327
2. Aigner K, Forche G, Kneussl M, et al. Ö sterreichische Gesellschaft fü r Lungenerkrankungen: Konsensus zur Diagnostik und Therapie von Asthma bronchiale bei Erwachsenen. Wien Klin Wochenschr 2004;116:339-345
3. British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network. British Guidelines on the management of asthma. Thorax 2003;58:i1-i94
4. Global Initiative for Asthma (GINA): global strategy for asthma management and prevention: NHBLI/WHO Workshop Report. Bethesda: National Institute of Heart, Lung and Blood Institute, 2002; Publication No. 02-3659
5. Global Strategy for Asthma Management and Prevention, revised 2006. Available at http://www.ginasthma.org [Last accessed 9 September 2007]
6. Rabe K, Vermeire P, Soriano J, et al. Clinical management of asthma in 1999. The Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000; 16:802-807
7. Lei CKW, deGuia TS, Kim Y-Y, et al. Asthma control in the Asia-Pacific region: the Asthma Insights and Reality in Asia-Pacific study (AIRIAP). J Allergy Clin Immunol 2003;111:263-268
8. Juniper EF, O'Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Resp J 1999;14:902-907
9. Juniper EF, Buist AS, Cox FM, et al. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest 1999;115:1265-1270
10. Bousquet J, Jeffery PK, Busse WW, et al. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161:1720-1745
11. Haahtela T, Klaukka T, Koskela K, et al. Asthma programme in Finland: a community problem needs community solutions. Thorax 2001;56:806-814
12. Haahtela T, Tuomisto LE, Pietinalho A, et al. A 10 year asthma programme in Finland: major change for the better. Thorax 2006;68:663-670
13. Salmeron S, Liard R, Elkharrat D, Muir J, et al. Asthma severity and adequacy of management in accident and emergency departments in France: a prospective study. Lancet 2001;358:629-635
14. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 2004;170:836-844
15. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1406-1411
16. Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial). BMJ 2003;327:891
17. Nelson H, Busse W, Kerwin E, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000;106:1088-1095
18. Price DB, Hernandez D, Magyar P, et al. for the Clinical Outcomes with Montelukast as a Partner Agent to Corticosteroid Therapy (COMPACT) International Study Group. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003;58:211-216
19. Carroll N, Carello S, Cooke C, et al. Airway structure and inflammatory cells in fatal attacks of asthma. Eur Respir J 1996;9:709-715
20. Kraft M, Djukanovic R, Wilson S., et al. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996;154:1505-1510
21. Martin RJ. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol 2002;109S:447-460
22. Virchow JC, Bachert C. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respiratory Med 2006;100:1952-1959
23. Korn D, Van den Brande P, Potvin E, et al. Efficacy of add-on montelukast in patients with non-controlled asthma: a Belgian open-label study. Curr Med Res Opin 2009;25:489-497
24. Keith P, Koch C, Djandji M, et al. Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). Canad Respir J 2009;16 (Suppl. A):17A-24A